Endomorphin-1

From WikiMD's WELLNESSPEDIA

Endomorphin_1.svg

Endomorphin-1 is an endogenous opioid peptide that is considered to be one of the most potent and selective agonists for the mu-opioid receptor (MOR). It is part of the endomorphin family, which also includes Endomorphin-2. These peptides are involved in modulating pain and other physiological functions.

Structure[edit]

Endomorphin-1 is a tetrapeptide with the amino acid sequence Tyr-Pro-Trp-Phe-NH2. This sequence is crucial for its high affinity and selectivity towards the mu-opioid receptor.

Function[edit]

Endomorphin-1 primarily functions by binding to the mu-opioid receptor, which is a G-protein coupled receptor. Upon binding, it activates intracellular signaling pathways that result in analgesic effects. This makes Endomorphin-1 a significant target for pain management research.

Distribution[edit]

Endomorphin-1 is widely distributed in the central nervous system (CNS), particularly in areas associated with pain modulation, such as the periaqueductal gray, dorsal horn of the spinal cord, and various regions of the brain including the hypothalamus and amygdala.

Pharmacology[edit]

Endomorphin-1 exhibits high affinity and selectivity for the mu-opioid receptor, which distinguishes it from other endogenous opioids like beta-endorphin and enkephalins. Its binding to the mu-opioid receptor results in potent analgesic effects, making it a potential candidate for developing new pain therapeutics.

Clinical Significance[edit]

Due to its potent analgesic properties, Endomorphin-1 is being studied for its potential use in pain management. Unlike traditional opioid drugs, Endomorphin-1 may offer pain relief with a lower risk of side effects such as addiction and tolerance.

Research[edit]

Ongoing research is focused on understanding the detailed mechanisms of Endomorphin-1's action, its potential therapeutic applications, and the development of analogs with improved pharmacological profiles.

See also[edit]

References[edit]


External links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.